Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

Angiosarcoma of the scalp with complete response to a biweekly gemcitabine and docetaxel (GEMDOC) chemotherapy regimen.

Angiosarcoma is a rare, aggressive soft-tissue sarcoma with a high rate of recurrence and distant metastasis. Only a few cases of angiosarcoma involving the scalp have been reported in the literature. We describe a case involving a 75-year-old woman who presented to the emergency department at the Detroit Medical Center with multiple painful scalp lesions. She had had similar lesions intermittently for several years that apparently had responded to treatment with antifungal creams, but those occurring in the 6 months before her presentation had not responded to that therapy. The final diagnosis was a metastatic angiosarcoma. The patient achieved complete remission following treatment with a combination chemotherapy regimen consisting of gemcitabine (1,500 mg/m²) and docetaxel (50 mg/m²) administered biweekly. The patient was free of disease at the 15-month follow-up. This regimen is well tolerated and should be considered, especially in elderly patients and patients with comorbid conditions who may not tolerate other chemotherapeutic regimens.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app